Scarica l'app Stockscreener
33.19
9.02%
-3.29
Dopo l'orario di chiusura:
33.18
-0.010
-0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$36.48
Aprire:
$36.8
Volume 24 ore:
1.82M
Relative Volume:
2.36
Capitalizzazione di mercato:
$1.90B
Reddito:
$205.63M
Utile/perdita netta:
$40.57M
Rapporto P/E:
50.30
EPS:
0.6599
Flusso di cassa netto:
$52.37M
1 W Prestazione:
-6.45%
1M Prestazione:
+4.01%
6M Prestazione:
+41.47%
1 anno Prestazione:
+309.25%
Intervallo 1D:
$33.00
$37.49
Intervallo di 1 settimana:
$33.00
$40.22
Portata 52W:
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.19 | 1.90B | 205.63M | 40.57M | 52.37M | 0.6599 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-05 | Iniziato | Guggenheim | Buy |
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.6% Following Insider Selling - MarketBeat
Aug Weekly: Can Stoke Therapeutics Inc grow without external fundingMarket Growth Review & Stock Market Timing Techniques - baoquankhu1.vn
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 33,243 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock - MarketBeat
Insider Sell: Adrian Krainer Sells 33,243 Shares of Stoke Therap - GuruFocus
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Highs Report: Is Stoke Therapeutics Inc in a long term uptrendPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock hits 52-week high at 39.88 USD By Investing.com - Investing.com Canada
Morgan Stanley Smith Barney files Rule 144 notice listing 58,769 and 31,739 STOK shares (STOK) - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Hits New 52-Week HighStill a Buy? - MarketBeat
Stoke Therapeutics earnings in focus amid Dravet trial progress - Investing.com South Africa
Stoke Therapeutics earnings in focus amid Dravet trial progress By Investing.com - Investing.com India
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6%Still a Buy? - MarketBeat
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
A Look At Stoke Therapeutics (STOK) Valuation After NEJM Zorevunersen Dravet Syndrome Data Publication - simplywall.st
Stoke Therapeutics Hits New 52-Week High of $39.81, Up 146.41% - Markets Mojo
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Rhenman & Partners Asset Management AB Invests $5.88 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Biogen’s Dravet And SMA Advances Add Depth To Long Term Story - Sahm
Can Stoke Therapeutics Inc. stock deliver sustainable ROE2026 WrapUp & Smart Allocation Stock Reports - Naître et grandir
Vanguard Group Inc. Buys 217,616 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rate Cut: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARWeekly Stock Report & Stepwise Swing Trade Plans - baoquankhu1.vn
How Investors May Respond To Stoke Therapeutics (STOK) NEJM Data And 2027 FDA Filing Timeline - Yahoo Finance
Insider Sell: Adrian Krainer Sells 7,229 Shares of Stoke Therape - GuruFocus
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - The AI Journal
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
Stoke Therapeutics (STOK) director sells 7,229 shares under 10b5-1 plan - Stock Titan
Is Stoke Therapeutics (STOK) Still Attractive After A 346% One Year Share Price Surge - simplywall.st
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith By Investing.com - Investing.com Australia
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith - Investing.com South Africa
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith - TipRanks
Stoke Therapeutics (NASDAQ: STOK) awards CEO Ian F. Smith $697,125 2025 bonus equivalent - Stock Titan
STOK: Phase 3 Dravet study nears full enrollment, with strong efficacy and broad market potential - TradingView
Stoke Therapeutics stock hits 52-week high at 38.8 USD By Investing.com - Investing.com Nigeria
STOK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year HighWhat's Next? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 38.8 USD - Investing.com India
Portfolio Shifts: What dividend growth rate does Stoke Therapeutics Inc offerJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
STOK PE Ratio & Valuation, Is STOK Overvalued - Intellectia AI
Stoke Therapeutics (STOK) Investor Outlook: A Promising Biotech with 17.3% Upside Potential - DirectorsTalk Interviews
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Risk Analysis: What is the earnings history of Stoke Therapeutics IncJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock²
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):